IDEAYA Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 30J.SG | RCUS | 9966.HK | 688382.SS | IOVA | IMCR | |
|---|---|---|---|---|---|---|
| Market cap | 2.78B | 2.43B | 6.43B | 8.38B | 3.94B | 1.51B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -6.2 | -21.0 | -43.8 | -44.4 | -37.7 |
| Price/book | 2.9 | 3.8 | 3.3 | 6.6 | 5.4 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +12.80% | −1.28% | −39.84% | −48.70% | +276.62% | −7.49% |
| Today | +0.17% | +2.12% | +1.68% | +4.33% | −1.47% | −2.66% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 30J.SG news ›IDEAYA Biosciences (NASDAQ:IDYA) Given New $52.00 Price Target at Guggenheim
Posted by Mitch Edgeman on Nov 4th, 2026 IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price objective decreased by equities researchers at Guggenheim from $57.00 to $52.00 in a research report issued on Wednesday, Benzinga…
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
Nov 04, 2026, 06:00 ET SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today…
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of... The stock options have an exercise price of $32.89 per share, which is equal…
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Nov 03, 2026, 06:00 ET SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted…
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results
Posted by Sarita Garza on Nov 3rd, 2026 View Our Latest Stock Report on IDEAYA Biosciences IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research…
Research Analysts’ Weekly Ratings Updates for IDEAYA Biosciences (IDYA)
IDEAYA Biosciences (NASDAQ: IDYA) has recently received a number of price target changes and ratings updates: 10/19/2026 – IDEAYA Biosciences had its “market outperform” rating reaffirmed by Citigroup. 10/16/2026 – IDEAYA Biosciences is…
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & IDEAYA Biosciences (NASDAQ:IDYA)
Posted by Michael Walen on Oct 24th, 2026 IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast…
IDEAYA Biosciences CEO sells 26,338 shares
3 E Network Signs Core 9 MVA Power Distribution Agreement for Mikkeli AI Compute Center in Finland J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area Merck…
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
Oct 19, 2026, 06:00 ET Prior tebentafusp (2L) (N=15) All presentations will take place on Saturday, October 24th, 2026, 12:00-12:45pm (CEST): 2092P (Poster Presentation)Title: Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com3
- themarketsdaily.com3
- defenseworld.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.